Press releases
- Aldeyra Therapeutics Highlights Recent Preclinical Data in Obesity, Atopic Dermatitis, Pain, and Alcoholic Hepatitis, and Announces Planned Pivotal Clinical Trial in Retinitis Pigmentosa, at 2024 Research & Development Day
- Aldeyra Therapeutics to Host Research & Development Day on April 25, 2024
- Aldeyra Therapeutics Announces Clinical Development Plan for Resubmission of New Drug Application for Reproxalap in Dry Eye Disease
- Ligand Reports Fourth Quarter and Full Year 2023 Financial Results
- Aldeyra Therapeutics to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
More ▼
Key statistics
On Friday, Aldeyra Therapeutics Inc (137:STU) closed at 3.78, 174.62% above the 52 week low of 1.38 set on Oct 24, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 3.91 |
---|---|
High | 3.91 |
Low | 3.77 |
Bid | 3.80 |
Offer | 3.96 |
Previous close | 3.85 |
Average volume | 154.00 |
---|---|
Shares outstanding | 59.41m |
Free float | 48.95m |
P/E (TTM) | -- |
Market cap | 247.16m USD |
EPS (TTM) | -0.6375 USD |
Data delayed at least 15 minutes, as of May 03 2024.
More ▼